Competition | Ceribell

Simplicity Without Sacrifice

Point-of-care EEG that’s fast, dependable, and designed for any trained healthcare provider.

Why Simplicity Matters?

In an emergency, there’s no time for a complex setup. You need answers immediately.

Ceribell helps you get the answers you need, when you need them, because every minute matters.

Our Design

Imagine spending precious minutes cleaning a device after every use and still not knowing if it’s truly free of infection risk.

We’ve simplified your workflow with a fully disposable headband, eliminating cleaning steps while also reducing infection risk for you and your hospital.

Imagine you are the lead on bringing in a POC solution that will be applied by over a hundred different nurses and residents. Simplicity scales.

Backed by peer-reviewed studies, Ceribell’s wet electrodes provide a stable, lasting signal with consistent performance across settings.^1,2 Dry electrodes may show impedance and signal limitations.³

Award-Winning Design Recognized for Innovation

Why Design Matters

Montage Sufficient for Seizure Capture

14 of 8,708 EEGs recorded over 4 years showed focal parasagittal seizures⁴

Read Paper

<1% of EEGs showed parasagittal seizures, all of which were visible in temporal channels and thus would be captured on Ceribell montage⁵

Read Paper

95% concordance diagnosis or ruling out of seizure activity between conventional and reduced montage like Ceribell⁶

Read Paper

Comparable 72h in-hospital seizure risk forecasting with Ceribell vs. conventional EEG⁷

Read Paper

Learn More About the Device

Proven AI Performance

Consistently Updated Using Your Feedback

AI trained on patients outside the ICU or ED, or using different hardware,

may not perform accurately when applied to ICU or ED patients.⁸

Clarity AI Validated in 35+ Publications & Abstracts*

Clarity Study

Clarity offers 24/7 EEG monitoring with consistently high performance for detecting non-convulsive status epilepticus⁹

Read Poster

AccuRASE Study

An independent study from Yale, published in Neurology as Level II evidence, reinforces the clinical value of Clarity¹⁰

Read Study

Intuitive, Secure Portal

Real-time, remote EEG monitoring and management

Pre-annotated EEG insights on desktop or mobile

One of 51 companies with FedRAMP High authorization¹¹

New features available to help deliver speed, control, and confidence

Learn More About the Ceribell Portal

The Evidence Leader

Ceribell is backed by 45 peer-reviewed publications,* including multi-center clinical studies like DECIDE¹², SAFER-EEG^7,13, and AccuRASE¹⁰.

See Evidence

DECIDE TRIAL:

Ceribell significantly improved clinical accuracy and confidence¹²

Improved clinical accuracy graphic

Read Study

AccuRASE Study:

An independent study from Yale, published in Neurology as Level II evidence, reinforces the clinical value of Clarity_v6¹⁰

Read Study

SAFER-EEG TRIAL:

Performance of the 2HELPS2B score with Ceribell is comparable to conventional EEG for forecasting seizure risk in acutely ill patients⁷

Read Study

Sub-analysis of SAFER-EEG TRIAL:

Shorter ICU length of stays and improved patient outcomes with Ceribell compared to conventional EEG only¹³

Read Study

Customer Support

Comprehensive, hands-on customer service with support before, during, and after program launch.

Demonstrated Value

NTAP-eligible device offering up to $913.90 per eligible patient¹⁴**, with demonstrated LOS^13,15 and transfer reduction^16,17

Value Drivers

Existing CPT codes¹⁸
Reduce patient transfers^16,17
Potential CC/MCC and DRG coverage following seizure diagnosis¹⁵
Potential NTAP payments¹⁴

Cost Savings

Fewer anti-seizure medications^19,20
Shorter hospital and ICU length of stay^13,15
Fewer EEG tech overtime costs²⁰
Avoid ICU admission for seizure monitoring²¹

The Evidence Supports Ceribell’s Economic Value

Review of 12 peer-reviewed studies confirms Ceribell helps refine clinical decisions, reduce resource use, and improve hospital margins.²²

Read Study

Contact us for real-world hospital examples

When evaluating the true cost of point-of-care EEG, be sure to factor in:

Number of devices required based on battery life

Risk of hospital-acquired infections (HAIs)

Set-up time, interpretation, and decision-making delays

Time and personnel needed to train ED and ICU teams

Potential IT security vulnerabilities

Resources required to launch and sustain new technology

Ceribell delivers a proven, cutting-edge solution with no hidden fees or downstream burdens – just streamlined workflows, reliable support, and measurable cost savings.

References and Citations

1. Kamousi, B., et al. (2019) Clin Neurophysiol Practice. 4:69-75
2. Alsherbini, K., et al. (2024) Neurocritical Care Society 2024 Annual Meeting Poster
3. Shad, E.H.T., et al. (2020) IEEE Sens. J. 20(24):14565-14577
4. Pedley, T., et al. (1981) Ann Neurol. 9:142-149
5. Gururangan, K., et al. (2019) Neurocrit Care, 32(1):193-197
6. Westover, M.B., et al. (2020) Neurocrit Care. 33(2):479-490
7. Kalkach-Aparicio, M., et al. (2024) Neurology. 103(2): e209621
8. McLaren, J.R., et al. (2025) Epilepsia. 66(6):1838-1842
9. Puranik, T., et al., (2025) Neurocritical Care Society Annual Meeting Poster
10. Sheikh, Z., et al. (2024) Neurology 104 (2)
11. Ceribell, Inc., (2025, April 30) [Press release]
12. Vespa, P.M., et al. (2020) Crit Care Med. 48(9):1249-1257
13. Desai, M., et al. (2025) Neurocrit Care. 42(1):108-117
14. CMS FY 2024 IPPS Final Rule. CMS-1785-F, 88 Fed. Reg. 58927-58930, Aug. 28, 2023
15. Eberhard, E.,etal.(2023) J Neurosci Nurs. 55(5):157-163
16. Madill, E.S., et al. (2022) Epileptic Disorders. 24(3):507-516

17. Ward, J., et al. (2023) Front. Digit. Health. 5(1)
18. AMA CPT 2025 Professional Edition. CMS 2025 Physician Fee Schedule
19. Ney, J.P., et al. (2021) J Med Econ. 24(1):318-327
20. Kozak, R., et al. (2023). JACEP Open. 4(4).
21. Ceribell, Inc. (2025) [White Paper] The Impact of Ceribell at the Bedside.
22. Green, A., et al. (2024). J Med Econ. 27(1):51-61

* Data as of Oct 2025
** For informational and illustrative purposes only. Patient care decisions must be made solely by licensed health care professionals. This is not legal or financial advice and not intended to increase or maximize reimbursement. Hospitals and providers are solely responsible for compliance with Medicare and other payer policies. Information provided does not represent the reimbursement of any individual facility – results may vary. Ceribell does not guarantee reimbursement, MS-DRG payment, NTAP eligibility or coverage for the diagnosis of ESE. For guidance on coding, coverage and payment policies, consult your Medicare Contractor, reimbursement specialists, and/or legal counsel.

What Sets Ceribell Apart

Your partner in delivering fast, dependable, and evidence-backed point-of-care EEG – designed with your team in mind

Simplicity Without Sacrifice

Why Simplicity Matters?​

In an emergency, there’s no time for a complex setup. You need answers immediately.

Ceribell helps you get the answers you need, when you need them, because every minute matters. ​

Our Design

Award-Winning Design Recognized for Innovation

Montage Sufficient for Seizure Capture​

14 of 8,708 EEGs recorded over 4 years showed focal parasagittal seizures4

<1% of EEGs showed parasagittal seizures, all of which were visible in temporal channels and thus would be captured on Ceribell montage5

95% concordance diagnosis or ruling out of seizure activity between conventional and reduced montage like Ceribell6

Comparable 72h in-hospital seizure risk forecasting with Ceribell vs. conventional EEG7

Proven AI Performance

Clarity AI Validated in 35+ Publications & Abstracts*

Clarity Study

AccuRASE Study

Intuitive, Secure Portal

Real-time, remote EEG monitoring and management

Pre-annotated EEG insights on desktop or mobile

One of 51 companies with FedRAMP High authorization11

New features available to help deliver speed, control, and confidence

The Evidence Leader

Ceribell is backed by 45 peer-reviewed publications,* including multi-center clinical studies like DECIDE12, SAFER-EEG7,13, and AccuRASE10.​

DECIDE TRIAL:

Ceribell significantly improved clinical accuracy and confidence12

AccuRASE Study:

An independent study from Yale, published in Neurology as Level II evidence, reinforces the clinical value of Clarityv610

SAFER-EEG TRIAL:

Performance of the 2HELPS2B score with Ceribell is comparable to conventional EEG for forecasting seizure risk in acutely ill patients7

Sub-analysis of SAFER-EEG TRIAL:

Shorter ICU length of stays and improved patient outcomes with Ceribell compared to conventional EEG only13

Customer Support

Demonstrated Value

Value Drivers

Existing CPT codes18

Reduce patient transfers16,17

Potential CC/MCC and DRG coverage following seizure diagnosis15

Potential NTAP payments14

Cost Savings

Fewer anti-seizure medications19,20

Shorter hospital and ICU length of stay13,15

Fewer EEG tech overtime costs20

Avoid ICU admission for seizure monitoring21

The Evidence Supports Ceribell’s Economic Value

When evaluating the true cost of point-of-care EEG, be sure to factor in:

Number of devices required based on battery life​

Risk of hospital-acquired infections (HAIs)​

Set-up time, interpretation, and decision-making delays​

Time and personnel needed to train ED and ICU teams​

Potential IT security vulnerabilities​

Resources required to launch and sustain new technology

Resources

Why Simplicity Matters?

Ceribell helps you get the answers you need, when you need them, because every minute matters.

Montage Sufficient for Seizure Capture

14 of 8,708 EEGs recorded over 4 years showed focal parasagittal seizures⁴

<1% of EEGs showed parasagittal seizures, all of which were visible in temporal channels and thus would be captured on Ceribell montage⁵

95% concordance diagnosis or ruling out of seizure activity between conventional and reduced montage like Ceribell⁶

Comparable 72h in-hospital seizure risk forecasting with Ceribell vs. conventional EEG⁷

One of 51 companies with FedRAMP High authorization¹¹

Ceribell is backed by 45 peer-reviewed publications,* including multi-center clinical studies like DECIDE¹², SAFER-EEG^7,13, and AccuRASE¹⁰.

Ceribell significantly improved clinical accuracy and confidence¹²

An independent study from Yale, published in Neurology as Level II evidence, reinforces the clinical value of Clarity_v6¹⁰

Performance of the 2HELPS2B score with Ceribell is comparable to conventional EEG for forecasting seizure risk in acutely ill patients⁷

Shorter ICU length of stays and improved patient outcomes with Ceribell compared to conventional EEG only¹³

Existing CPT codes¹⁸

Reduce patient transfers^16,17

Potential CC/MCC and DRG coverage following seizure diagnosis¹⁵

Potential NTAP payments¹⁴

Fewer anti-seizure medications^19,20

Shorter hospital and ICU length of stay^13,15

Fewer EEG tech overtime costs²⁰

Avoid ICU admission for seizure monitoring²¹

Number of devices required based on battery life

Risk of hospital-acquired infections (HAIs)

Set-up time, interpretation, and decision-making delays

Time and personnel needed to train ED and ICU teams

Potential IT security vulnerabilities